Loading
A phase 2 trial of Sutetinib Maleate Capsule in non-small-cell lung cancer, run by Teligene US, now recruiting.
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC is a phase 2 interventional study registered as NCT06010329 by Teligene US, with 66 participants planned, started 2023-12-27 and due to reach its primary completion in 2027-12. Interventions recorded: Sutetinib Maleate Capsule.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/